PubRank

Stephen R Durham

Author PubWeight™ 84.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009 4.10
2 Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004 2.40
3 Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet 2005 2.07
4 Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003 2.01
5 Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003 1.94
6 Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 1.87
7 Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007 1.85
8 Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol 2006 1.68
9 Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009 1.65
10 Tregs and allergic disease. J Clin Invest 2004 1.64
11 Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011 1.62
12 Mechanisms of immunotherapy. J Allergy Clin Immunol 2004 1.45
13 Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008 1.43
14 Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008 1.38
15 Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013 1.33
16 Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005 1.30
17 Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007 1.28
18 Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2010 1.27
19 Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004 1.26
20 Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 1.26
21 Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2007 1.22
22 Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets 2008 1.15
23 The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 2003 1.13
24 Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007 1.12
25 Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol 2005 1.12
26 Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc 2004 1.09
27 Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003 1.08
28 Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol 2012 1.08
29 Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol 2012 1.08
30 Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007 1.06
31 EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012 1.04
32 Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods 2012 1.04
33 The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006 1.03
34 Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J 2009 1.03
35 A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol 2013 1.02
36 Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011 1.02
37 Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol 2003 1.02
38 IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005 1.01
39 Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002 1.00
40 Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003 0.99
41 CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol 2002 0.99
42 Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 0.98
43 Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomised, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray. Rhinology 2005 0.98
44 IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am 2006 0.97
45 IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol 2012 0.96
46 Germinal-centre reactions in allergic inflammation. Trends Immunol 2006 0.95
47 Allergen immunotherapy and tolerance. Allergol Int 2013 0.92
48 NHS allergy services in the UK: proposals to improve allergy care. Clin Med 2002 0.91
49 One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol 2011 0.90
50 Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther 2013 0.90
51 Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol 2005 0.89
52 Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am 2011 0.88
53 Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004 0.87
54 Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med 2002 0.86
55 Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res 2006 0.85
56 The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2010 0.84
57 Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax 2013 0.83
58 CXCR1+CD4+ T cells in human allergic disease. J Immunol 2004 0.83
59 Postnasal drip and chronic cough: An open interventional study. Respir Med 2009 0.82
60 Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol 2012 0.82
61 Tobacco industry lobbyists and their health-care clients. Lancet 2013 0.82
62 Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am 2011 0.81
63 Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol 2012 0.81
64 Immunological responses to allergen immunotherapy. Clin Allergy Immunol 2004 0.81
65 Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol 2013 0.80
66 Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother 2012 0.79
67 Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002 0.78
68 Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy 2013 0.77
69 Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? J Allergy Clin Immunol 2009 0.77
70 Immunomodulatory treatment strategies for allergic diseases. Curr Drug Targets Inflamm Allergy 2003 0.76
71 Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol 2008 0.76
72 Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med 2006 0.75
73 Treatment of seasonal allergic rhinitis: desensitisation for hay fever works. BMJ 2003 0.75
74 Perennial rhinitis. BMJ 2007 0.75
75 Allergen injection immunotherapy. Clin Allergy Immunol 2002 0.75
76 Silk contact anaphylaxis. Contact Dermatitis 2014 0.75
77 Tradition and innovation: finding the right balance. J Allergy Clin Immunol 2007 0.75
78 Biomarkers of tolerance in response to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess 2013 0.75
79 Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008 0.75